ArticleNature immunology2025
β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus.
Erratum issuedAbstract read
In one paragraph
Article in Nature immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Maladaptive trained immunity as a hematopoietic stem cell driver of inflammaging.Nature aging · 2026Article
- Neutrophil-based immunotherapy: A metabolic lens on mechanisms and therapeutic implications.Clinical and translational medicine · 2026Review
- Early Environments, Lasting Effects: Air Pollution, Microbes, and Respiratory Infection Risk in Children.Pediatric pulmonology · 2026Review
- Lung Microbiome Diversity, Infection Dynamics, and Microbe-Mediated Cross-Protection.MicrobiologyOpen · 2026Review
- Article
- Role of gut microbiota metabolites in maintaining intestinal health and preventing weaning-associated diarrhea in piglets.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Review
- A glycopeptide hydrogel confers protection and treatment in sepsis via recruitment and training of macrophages.Materials today. Bio · 2026Article
- Type 2 immune history imprints local training in nerve and airway associated interstitial macrophages (NAMs) for disease tolerance during lethal respiratory viral infection.Research square · 2026Article
- Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response.Nature communications · 2026Article
- Trained immunity-based mucosal immunotherapies for preventing respiratory infections: a translational, evidence-graded appraisal of platforms, populations, and the protection-immunopathology balance.Frontiers in medicine · 2026Review
- Neutrophil Heterogeneity after Myocardial Infarction.Journal of innate immunity · 2026Review
- Trained immunity and related memory responses in lung health and disease.Frontiers in immunology · 2026Review
- β-Glucan in antiviral defense: mechanisms, immune modulation, and therapeutic prospects.Folia microbiologica · 2025Review
- β-Glucan pretreatment activates lectin pathway to maintain the function of intestinal Th17 cells for infectious enteritis protection.Zoological research · 2025Article
- Review
- Trained immunity: induction of an inflammatory memory in disease.Cell research · 2025Review
- Mitochondrial dysfunction in myeloid cells: a central deficit in autoimmune diseases.Trends in immunology · 2025Review
- Hypoxia induces histone clipping and H3K4me3 loss in neutrophil progenitors resulting in long-term impairment of neutrophil immunity.Nature immunology · 2025Article
- Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
19 authors.
Nargis Khan *Department of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins Christie Laboratories, McGill University, Montréal, Québec, Canada. nargis.khan1@ucalgary.ca.ORCID http://orcid.org/0000-0002-8006-5116
Kim A Tran *Department of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins Christie Laboratories, McGill University, Montréal, Québec, Canada.ORCID http://orcid.org/0000-0003-0299-7417
Raphael ChevreInstitute of Experimental Pathology, Centre of Molecular Biology of Inflammation, Münster, Germany.
Veronica LocherCommittee on Immunology, University of Chicago, Chicago, IL, USA.
Mathis RichterInstitute of Experimental Pathology, Centre of Molecular Biology of Inflammation, Münster, Germany.ORCID http://orcid.org/0000-0002-3110-6137
Sarah SunGenetics, Genomics, and Systems Biology, University of Chicago, Chicago, IL, USA.
Mina SadeghiDepartment of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins Christie Laboratories, McGill University, Montréal, Québec, Canada.ORCID http://orcid.org/0000-0001-5110-3817
Erwan PernetDepartment of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins Christie Laboratories, McGill University, Montréal, Québec, Canada.
Andrea Herrero-CerveraInstitute of Experimental Pathology, Centre of Molecular Biology of Inflammation, Münster, Germany.ORCID http://orcid.org/0000-0001-6490-6504
Alexandre GrantDepartment of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins Christie Laboratories, McGill University, Montréal, Québec, Canada.
Ahmed SaifDepartment of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins Christie Laboratories, McGill University, Montréal, Québec, Canada.
Jeffrey DowneyDepartment of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins Christie Laboratories, McGill University, Montréal, Québec, Canada.
Eva KaufmannDepartment of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins Christie Laboratories, McGill University, Montréal, Québec, Canada.
Shabaana Abdul KhaderDepartment of Microbiology, University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-9545-4982
Philippe JoubertDepartment of Molecular Biology, Medical Biochemistry and Pathology, Laval University, Québec City, Québec, Canada.
Luis B BarreiroCommittee on Immunology, University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-9456-367X
Bryan G YippCalvin, Phoebe and Joan Snyder Institute for Chronic Diseases, Department of Critical Care, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID http://orcid.org/0000-0002-5887-9551
Oliver SoehnleinInstitute of Experimental Pathology, Centre of Molecular Biology of Inflammation, Münster, Germany.ORCID http://orcid.org/0000-0002-7854-0694
Maziar DivangahiDepartment of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins Christie Laboratories, McGill University, Montréal, Québec, Canada. maziar.divangahi@mcgill.ca.ORCID http://orcid.org/0000-0002-1254-6110
Funding
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007090 · NIAID · UNIVERSITY OF CHICAGO · PI Peter Aidan Savage · 1985 to 2026
$11.7MTargeting trained immunity and Th1/Th17 axis with combination adjuvantsU01AI160406 · NIAID · WASHINGTON UNIVERSITY · PI DIVANGAHI, MAZIAR, KAUSHAL, DEEPAK · 2021 to 2025
$3.0MGates Foundation INV-003360NIAID NIH HHS T32 AI007090NIAID NIH HHS U01 AI160406U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI160406
Abstract
Disease tolerance is an evolutionarily conserved host defense strategy that preserves tissue integrity and physiology without affecting pathogen load. Unlike host resistance, the mechanisms underlying disease tolerance remain poorly understood. In the present study, we investigated whether an adjuvant (β-glucan) can reprogram innate immunity to provide protection against influenza A virus (IAV) infection. β-Glucan treatment reduces the morbidity and mortality against IAV infection, independent of host resistance. The enhanced survival is the result of increased recruitment of neutrophils via RoRγt
Indexed as
beta-GlucansImmune ToleranceInfluenza A virusNeutrophilsOrthomyxoviridae InfectionsAnimalsHumansImmunity, InnateInterferon Type IInterleukin-10LungMiceMice, Inbred C57BLMice, Knockoutbeta-GlucansInterferon Type IInterleukin-10
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.